| |
| |
| Exchange: |
N/A |
| Security
Type: |
N/A |
| Shares
Out: |
90,552,000 |
| Market
Cap: |
2.35(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$18.07 - $59.1 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : 8 |
| Insider 3/6 Months : 8.6 |
|
| Guru Rank Number : 538 |
| Guru Rank Value : 3 |
| Guru Occurances : 1 |
|
|
|
|
|
| |
|
Company Profile PTC Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of clinically-differentiated medicines that provide benefits to patients with rare disorders. Co. has the following products, Translarna™ (ataluren) and Emflaza® (deflazacort), for the treatment of Duchenne muscular dystrophy, a rare, life threatening disorder. Co.'s gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS) include PTC- Aromatic L-Amino Acid Decarboxylase (AADC) for the treatment of AADC deficiency, a rare CNS disorder arising from reductions in the enzyme AADC that results from mutations in the dopa decarboxylase gene.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
7,700 |
7,700 |
7,700 |
| Total Buy Value |
$0 |
$198,736 |
$198,736 |
$198,736 |
| Total People Bought |
0 |
1 |
1 |
1 |
| Total Buy Transactions |
0 |
1 |
1 |
1 |
| Total Shares Sold |
12,650 |
46,717 |
118,423 |
274,885 |
| Total Sell Value |
$346,608 |
$1,311,200 |
$5,179,432 |
$12,751,476 |
| Total People Sold |
6 |
8 |
10 |
15 |
| Total Sell Transactions |
7 |
23 |
34 |
85 |
| End Date |
2024-01-21 |
2023-10-20 |
2023-04-21 |
2022-04-21 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Klein Matthew B. |
CHIEF EXECUTIVE OFFICER |
• • – |
2024-04-19 |
4 |
S |
$24.89 |
$83,669 |
D/D |
(3,361) |
225,807 |
|
- |
|
| Klein Matthew B. |
CHIEF EXECUTIVE OFFICER |
• • – |
2024-04-17 |
4 |
S |
$25.14 |
$32,851 |
D/D |
(1,307) |
229,168 |
|
-3% |
|
| Pauwels Eric |
CHIEF EXECUTIVE OFFICER |
• • – |
2024-04-17 |
4 |
S |
$25.14 |
$19,781 |
D/D |
(787) |
67,694 |
|
-3% |
|
| Golden Lee Scott |
EVP & CHIEF MEDICAL OFFICER |
• – – |
2024-04-02 |
4 |
S |
$28.37 |
$14,923 |
D/D |
(526) |
59,988 |
|
11% |
|
| Utter Christine Marie |
SVP, CHIEF ACCOUNTING OFFICER |
• – – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
16,900 |
52,428 |
|
- |
|
| Reeve Emma |
|
– • – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
11,200 |
|
- |
|
| Gravier Pierre |
CHIEF FINANCIAL OFFICER |
• – – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
22,100 |
55,800 |
|
- |
|
| Schmertzler Michael |
|
– • – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
8,000 |
123,266 |
|
- |
|
| Steele Glenn Jr Md |
|
– • – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
14,500 |
|
- |
|
| Almstead Neil Gregory |
CHIEF TECHNICAL OPS OFFICER |
• – – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
I/I |
870 |
4,576 |
|
- |
|
| Almstead Neil Gregory |
CHIEF TECHNICAL OPS OFFICER |
• – – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
25,000 |
86,202 |
|
- |
|
| Golden Lee Scott |
CHIEF MEDICAL OFFICER |
• – – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
22,600 |
60,514 |
|
- |
|
| Klein Matthew B. |
CHIEF EXECUTIVE OFFICER |
• • – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
70,000 |
230,475 |
|
- |
|
| Young Alethia |
|
– • – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
13,067 |
|
- |
|
| Boulding Mark Elliott |
EXEC. VP AND CLO |
• – – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
21,200 |
92,389 |
|
- |
|
| Bell William F. Jr. |
|
– • – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
10,333 |
|
- |
|
| Zeldis Jerome B |
|
– • – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
14,500 |
|
- |
|
| Smith Mary L. |
|
– • – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
13,813 |
|
- |
|
| Southwell David P |
|
– • – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
14,500 |
|
- |
|
| Jacobson Allan Steven |
|
– • – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
16,348 |
|
- |
|
| Okey Stephanie |
|
– • – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
4,000 |
9,867 |
|
- |
|
| Pauwels Eric |
CHIEF BUSINESS OFFICER |
• – – |
2024-02-15 |
4 |
A |
$0.00 |
$0 |
D/D |
24,300 |
68,481 |
|
- |
|
| Boulding Mark Elliott |
EXEC. VP AND CLO |
• – – |
2024-01-30 |
4 |
S |
$27.25 |
$21,637 |
D/D |
(794) |
71,189 |
|
5% |
|
| Pauwels Eric |
CHIEF BUSINESS OFFICER |
• – – |
2024-01-30 |
4 |
S |
$27.25 |
$9,974 |
D/D |
(366) |
44,181 |
|
5% |
|
| Utter Christine Marie |
SVP, CHIEF ACCOUNTING OFFICER |
• – – |
2024-01-30 |
4 |
S |
$27.25 |
$8,666 |
D/D |
(318) |
35,528 |
|
5% |
|
524 Records found
|
|
Page 1 of 21 |
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
| |
OE |
- Options Exercised |
A |
- Acquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
0.65 (2.57%) 
